

C17orf39 antibody - C-terminal region

Rabbit Polyclonal Antibody

Catalog # AI13614

Product Information

Application	WB
Primary Accession	Q8IVV7
Other Accession	NM_024052 , NP_076957
Reactivity	Human, Mouse, Rat, Rabbit, Zebrafish, Dog, Horse, Bovine
Predicted	Human, Rabbit, Chicken, Dog, Horse
Host	Rabbit
Clonality	Polyclonal
Calculated MW	33514

Additional Information

Gene ID	79018
Alias Symbol	MGC3048, C17orf39
Other Names	Glucose-induced degradation protein 4 homolog, Vacuolar import and degradation protein 24 homolog, GID4, C17orf39, VID24
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 50 ul of distilled water. Final anti-C17orf39 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
Precautions	C17orf39 antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information


Name	GID4
Synonyms	C17orf39, VID24
Function	Substrate-recognition subunit of the CTLH E3 ubiquitin- protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 (Probable) (PubMed: 29911972). Binds proteins and peptides with a Pro/N-degron consisting of an unmodified N-terminal Pro followed by a small residue, and has the highest affinity for the peptide Pro-Gly-Leu-Trp (PubMed: 29632410). Binds peptides with an N-terminal sequence of the type Pro-[Ala,Gly]- [Leu,Met,Gln,Ser,Tyr]-[Glu,Gly,His,Ser,Val,Trp,Tyr]. Does not bind

peptides with an acetylated N-terminal Pro residue (PubMed:[29632410](#)).

References

Ota T.,et al.Nat. Genet. 36:40-45(2004).
Zody M.C.,et al.Nature 440:1045-1049(2006).

Images



WB Suggested Anti-C17orf39 Antibody Titration: 0.2-1
µg/ml
Positive Control: Human Muscle

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.